Diagnostic psychiatric and somatic comorbidity in patients with depression in the Western Balkan countries
Open Access
- 2 January 2024
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (1) , e0295754
Abstract
Introduction: This paper aims to examine the frequency and significance of diagnostic comorbidity of psychiatric disorders and somatic diseases in a sample of patients with depression as well as present current psychopharmacological treatment of the patients in the sample. Methods: The subjects in this study sample were 489 patients from the four Western Balkan countries with current primary diagnosis of major depression according to ICD 10. Comorbid psychiatric disorders and non-psychiatric illnesses were noted according to ICD 10 criteria during the diagnostic interview and analysed later. Additionally, the pharmacological treatment (existing and newly introduced) for each patient was noted and analysed later. Results: At least one comorbid psychiatric disorder was present in 72.5% of patients. The most frequent were anxiety disorders (53.6%), specifically generalized anxiety disorder (20.2%); non-organic sleep disorders (50.7%), specifically insomnia (48.4%); and sexual dysfunctions (21.4%), specifically lack of sexual desire (20.2%). Comorbidity with any non-psychiatric illness was present in 80.3% of patients. The most frequent were circulatory system diseases (55.9%), specifically hypertension (45.9%); endocrine, nutritional and metabolic disorders (51.3%), specifically hyperlipidaemia (24.0%); and other non-psychiatric disorders (60.7%), specifically low back pain (22.7%). All patients received pharmacological treatment with different medications. Most patients received monotherapy or combination therapy of antidepressants, anxiolytics, antipsychotics and antiepileptics. The most frequently used antidepressants were escitalopram, sertraline, and duloxetine. The most frequently used anxiolytics were alprazolam and diazepam, the most used antiepileptic was pregabalin, and the most used antipsychotics were olanzapine, quetiapine, and aripiprazole. Conclusion: The results of the study confirm the results of previous research studies about the high prevalence of psychiatric and non-psychiatric comorbidities in patients with depression that were conducted in the past. It would be important if future studies could prove the importance of those comorbidities on clinical severity, choice of treatment, and its outcome in patients with depression.Keywords
This publication has 24 references indexed in Scilit:
- Multiple Pain Complaints in Patients With Major Depressive DisorderPsychosomatic Medicine, 2009
- Diagnostic co-morbidity in 2300 psychiatric out-patients presenting for treatment evaluated with a semi-structured diagnostic interviewPsychological Medicine, 2007
- The Clinical Pharmacokinetics of EscitalopramClinical Pharmacokinetics, 2007
- Prevalence, Severity, and Comorbidity of 12-Month DSM-IV Disorders in the National Comorbidity Survey ReplicationArchives of General Psychiatry, 2005
- Comorbidity in depressionActa Psychiatrica Scandinavica, 2003
- Duloxetine in treatment of anxiety symptoms associated with depressionDepression and Anxiety, 2003
- Depression, sleep physiology, and antidepressant drugsDepression and Anxiety, 2001
- Sertraline 50 mg daily: the optimal dose in the treatment of depressionInternational Clinical Psychopharmacology, 1995
- Comorbidity and treatment planning: Summary and future directions.Journal of Consulting and Clinical Psychology, 1992
- Comorbidity and treatment planning: Summary and future directions.Journal of Consulting and Clinical Psychology, 1992